Document text
Principal Investigator: Johannes Morstein
Organization: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Fiscal Year: 2023
Award: $163,080
Funding agency: National Cancer Institute
Project Summary
Significant progress in human cancer therapy in the last decade has been driven by conceptionally new
approaches to treating cancer, including cancer immunotherapy, cancer nanotherapy (e.g. liposomal doxorubicin
or mRNA vaccines), or new types of biologics and small molecules. I propose to develop new approaches to
targeting protein-membrane interactions that could yield unprecedented methods to modulate cancer signaling
and generate useful paradigms for pharmacology at large. The role of protein-membrane and drug-membrane
interactions will be explored and targeted on various levels, each highly relevant to cancer pharmacology:
1. Cancer signaling, a hallmark of cancer, is largely dependent on the recruitment of kinases (e.g. PI3K or PKC)
and GTPases (e.g. RAS) to hotspots localized at the inner plasma membrane leaflet. I aim to develop bifunctional
inhibitors with the capacity to modulate these interactions as a new approach to target cancer signaling.
2a. Membrane-integrated receptors are also key players in cellular signaling (e.g. enzyme-linked receptors or
GPCRs). Recently, a number of pharmacophores have been discovered that target these proteins directly from
the intramembrane space. These `Intramembrane pharmacophores' first partition into the membrane and then
engage their target through lateral diffusion and entry. I aim to systematically modulate membrane exposed
pharmacophore sites to explore principles governing the action of these pharmacophores which in turn will aid
in the discoveries of new intramembrane pharmacophores.
2b. The majority of bioactive molecules acts on membrane proteins or intracellular targets and therefore needs
to partition into or cross biological membranes. I propose to use combinatorial chemistry to discover new
principles and chemical structures that modulate and privilege pharmacophores for cellular uptake. These will
be tested in live cells using high throughput assays as a holistic approach to covering all possible uptake
mechanisms on the first level of screening (e.g. endocytosis, transporters, passive diffusion).
Combined, the proposed research will provide important insights into the functional role of protein-
membrane interactions in cancer signaling and their vulnerability to small molecule-based modulation.
Each of the proposed directions has the potential to yield fundamentally new and unprecedented
approaches to targeting cancer and other diseases.
My mentor and collaborators have extensive experience in cancer pharmacology, drug discovery, and the
biophysical characterization of protein-membrane interfaces and will provide the training needed to conduct the
proposed research. They will also provide the mentorship needed to acquire all skills and preliminary data
needed for a successful transition to an independent career in cancer research.
Terms: <1-Phosphatidylinositol 3-Kinase><Address><Area><Binding><Biologic Products><Biological><Biological Agent><Biological Products><C-K-RAS><Cancer Biology><Cancer Treatment><Cancers><Cell Body><Cell Communication and Signaling><Cell Membrane Permeability><Cell Signaling><Cell membrane><Cells><Chemical Structure><Chemistry><Complement><Complement Proteins><Conceptions><Cytoplasmic Membrane><Data><Development><Diffusion><Disease><Disorder><Doxorubicin Liposome><Drug Design><Drug Targeting><Drugs><Electrostatics><Endocytosis><Enzyme Gene><Enzymes><Event><Extracellular Signal-Regulated Kinase Gene><FK506 Binding Protein 12-Rapamycin Associated Protein 1><FKBP12 Rapamycin Complex Associated Protein 1><FRAP1><FRAP1 gene><FRAP2><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GPCR><GTP Phosphohydrolases><GTPases><Generalized Growth><Goals><Growth><Guanosine Triphosphate Phosphohydrolases><Guanosinetriphosphatases><High Throughput Assay><Human><Interdisciplinary Research><Interdisciplinary Study><Intracellular Communication and Signaling><Ion Channel><Ionic Channels><K-RAS2A><K-RAS2B><K-Ras><K-Ras 2A><K-Ras-2 Oncogene><KRAS><KRAS2><KRAS2 gene><Ki-RAS><Kinases><Lateral><Libraries><Link><Lipids><Liposomal Doxorubicin><Liposomal-Encapsulated Doxorubicin><MAP Kinase Gene><MAPK><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mechanistic Target of Rapamycin><Medication><Membrane><Membrane Channels><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Mentors><Mentorship><Methods><Mitogen-Activated Protein Kinase Gene><Modern Man><Molecular Interaction><Multidisciplinary Collaboration><Multidisciplinary Research><Natural Products><Nature><Oncogene K-Ras><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><Pathway interactions><Permeability><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacology><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Phosphotransferase Gene><Phosphotransferases><Plasma Membrane><Process><Property><Proteins><PtdIns 3-Kinase><RAFT1><RASK2><RNA vaccine><RNA-based vaccine><Receptor Protein><Research><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Structure-Activity Relationship><Surface Proteins><Testing><Tissue Growth><Training><Transphosphorylases><Type I Phosphatidylinositol Kinase><Type III Phosphoinositide 3-Kinase><WNT Signaling Pathway><WNT signaling><anti-cancer immunotherapy><anti-cancer research><anti-cancer therapy><anticancer immunotherapy><anticancer research><anticancer therapy><biologic><biological signal transduction><biologics><biopharmaceutical><biophysical characteristics><biophysical characterization><biophysical measurement><biophysical parameters><biophysical properties><biotherapeutic agent><cancer immunotherapy><cancer pharmacology><cancer research><cancer therapy><cancer-directed therapy><career><chemical structure function><combinatorial><combinatorial chemistry><convict><design><designing><developmental><diffused><diffuses><diffusing><diffusions><drug discovery><drug/agent><experience><guanosinetriphosphatase><high throughput screening><holistic approach><immune-based cancer therapies><immunotherapy for cancer><immunotherapy of cancer><inhibitor><innovate><innovation><innovative><insight><lipophilicity><mRNA vaccine><mRNA-based vaccine><mTOR><malignancy><mammalian target of rapamycin><membrane permeability><membrane structure><nano therapy><nanotherapy><naturally occurring product><neoplasm/cancer><new approaches><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic target><novel therapy target><ontogeny><pathway><pharmacologic><pharmacophore><plasmalemma><receptor><recruit><screening><screenings><skills><small molecule><social role><structure function relationship><uptake><v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog>